NSE: DRREDDY · 15 October 2026 · Pre-market update
- Dr. Reddy's Laboratories will be in focus at the market open following the receipt of a USFDA Form 483 with three observations for its FTO-9 manufacturing facility in Visakhapatnam. The inspection concluded recently, and the company has stated it will address the observations within the stipulated timeline.
- The United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection at the FTO-9 manufacturing facility located in Visakhapatnam, Andhra Pradesh, which ran from October 8 to October 9, 2026. Following the inspection, the regulatory body issued a Form 483 containing three observations.
- Trading volume was 0.69 times the 20-day average daily volume.
Dr. Reddy S Laboratories Company News Before Market Open
Dr. Reddy's Laboratories will be in focus at the market open following the receipt of a USFDA Form 483 with three observations for its FTO-9 manufacturing facility in Visakhapatnam. The inspection concluded recently, and the company has stated it will address the observations within the stipulated timeline.
The USFDA inspection results directly concern the FTO-9 manufacturing facility in Visakhapatnam. The issuance of a Form 483 with three observations requires a formal response and remedial action within a stipulated timeline. Prior session context shows the stock closed down 1.94% at 1,216.0 on October 14, 2026, ahead of this evening disclosure.
16.16 lakh shares traded on 14 October 2026. This compares with a 20-day average daily volume of 23.40 lakh shares (0.69 times). The five-day average daily volume was 19.44 lakh shares.
The USFDA inspection results directly concern the FTO-9 manufacturing facility in Visakhapatnam. The issuance of a Form 483 with three observations requires a formal response and remedial action within a stipulated timeline. Prior session context shows the stock closed down 1.94% at 1,216.0 on October 14, 2026, ahead of this evening disclosure.
Latest Company Developments
The United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection at the FTO-9 manufacturing facility located in Visakhapatnam, Andhra Pradesh, which ran from October 8 to October 9, 2026. Following the inspection, the regulatory body issued a Form 483 containing three observations.
Regulatory observations at key manufacturing sites can impact inspection clearance timelines and compliance sentiment for pending product approvals.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.16% on 30 June 2026. This compares with 13.19% on 31 March 2026, a change of -0.03 percentage points.
The filing reported 40 MF/UTI holders.
What to Watch Next
- Market reaction and trading volumes at the open following the disclosure of the USFDA inspection outcome.
- Management commentary or updates regarding the timeline for addressing the three Form 483 observations.
- Price action relative to the prior session's trading range between 1,209.6 and 1,234.4.
Other Dated Coverage
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026 — 13 October 2026
- Dr. Reddy's Laboratories in Focus After Setting Q2FY27 Earnings Date | 8 October 2026 — 8 October 2026
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.35% | 7 October 2026 — 7 October 2026
More Dr. Reddy S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Reddy S Laboratories company news?
The United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection at the FTO-9 manufacturing facility located in Visakhapatnam, Andhra Pradesh, which ran from October 8 to October 9, 2026. Following the inspection, the regulatory body issued a Form 483 containing three observations.
How strong was Dr. Reddy S Laboratories’s trading volume?
16.16 lakh shares traded, 0.69 times the 20-day average daily volume. The price and volume data are dated 14 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.